Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Eton Pharmaceuticals to post earnings of $0.10 per share and revenue of $22.3120 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%. On average, analysts expect Eton Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Eton Pharmaceuticals Stock Up 2.3%
ETON traded up $0.68 during midday trading on Tuesday, reaching $30.84. 272,204 shares of the company were exchanged, compared to its average volume of 342,265. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.57. The company’s fifty day moving average price is $21.94 and its 200 day moving average price is $18.48. The company has a market cap of $843.81 million, a price-to-earnings ratio of -171.60 and a beta of 0.82. Eton Pharmaceuticals has a one year low of $13.09 and a one year high of $32.31.
Institutional Investors Weigh In On Eton Pharmaceuticals
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Craig Hallum upped their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright upped their target price on Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a report on Friday, March 20th. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Zacks Research lowered Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eton Pharmaceuticals has an average rating of “Hold” and an average target price of $39.33.
View Our Latest Stock Report on ETON
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Read More
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
